No Data
Eli Lilly Tops Growth Factor Grades Among S&P Healthcare Holdings
The Best Dividend Stocks to Buy and Hold Forever
Johnson & Johnson Says FDA Approves Johnson & Johnson's TECNIS PureSee Lens for Cataract Surgery
J&J Wins FDA Nod for Tecnis PureSee Intraocular Lens
Johnson & Johnson's ECNIS PureSee IOL Gets FDA's Approval For Use In Cataract Surgery
Eli Lilly and Co (LLY.US) warns of potential risks associated with compounded low-cost weight-loss drugs containing tirzepatide.
Eli Lilly and Co has issued a warning regarding impurity issues in its combination weight-loss drug, citing potential toxicity and adverse immune responses that could pose health risks. Recent tests have also identified critical safety concerns in other areas, such as bacterial contamination and high levels of the toxic component endotoxin.
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
75487851 : bldp is waking up